Pancreatic Cancer Research

ResearcherSasebo Kyosai HospitalNo recent work listed

Haruo Iguchi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5055363329. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper

Papers 10

  1. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Co-author DOI 10.1097/mpa.0000000000001052↗
  2. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  3. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  4. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  5. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer. Last author DOI 10.3892/ijo.2017.3992↗
  6. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  7. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and de… Last author DOI 10.1097/mpa.0b013e3182550d77↗
  8. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model. Co-author DOI 10.3892/or.2012.1757↗
  9. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗
  10. [Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis]. Last author PMID 22139487↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Ioka · 4 shared papers, 2011–2018 · strength 0.18
  2. Junji Furuse · 4 shared papers, 2011–2018 · strength 0.18
  3. Shinichi Ohkawa · 3 shared papers, 2011–2018 · strength 0.14
  4. Takuji Okusaka · 3 shared papers, 2011–2018 · strength 0.13
  5. Masayuki Furukawa · 2 shared papers, 2016–2017 · strength 0.13
  6. Yoshito Komatsu · 3 shared papers, 2011–2017 · strength 0.12
  7. Akihito Tsuji · 2 shared papers, 2017–2018 · strength 0.12
  8. Masafumi Ikeda · 2 shared papers, 2016–2018 · strength 0.11
  9. Nobumasa Mizuno · 2 shared papers, 2016–2017 · strength 0.10
  10. Masaaki Oka · 2 shared papers, 2017 · strength 0.09
  11. Tomio Ueno · 2 shared papers, 2017 · strength 0.09
  12. Takashi Hatori · 2 shared papers, 2017 · strength 0.09
  13. Yoshitaro Shindo · 2 shared papers, 2017 · strength 0.09
  14. Nobuaki Suzuki · 2 shared papers, 2017 · strength 0.09
  15. Tetsuya Ikemoto · 2 shared papers, 2017 · strength 0.09
  16. Yuzo Umeda · 2 shared papers, 2017 · strength 0.09
  17. Mitsuo Shimada · 2 shared papers, 2017 · strength 0.09
  18. Hiroto Matsui Matsui · 2 shared papers, 2017 · strength 0.09
  19. Yusuke Nakamura · 2 shared papers, 2017 · strength 0.09
  20. Toshiyoshi Fujiwara · 2 shared papers, 2017 · strength 0.09
  21. Soichi Takiguchi · 1 shared paper, 2017 · strength 0.08
  22. Shoji Nakamori · 2 shared papers, 2011–2016 · strength 0.07
  23. Narikazu Boku · 2 shared papers, 2011–2016 · strength 0.07
  24. Teruhiko Yoshida · 1 shared paper, 2018 · strength 0.06
  25. Hiroshi Ishii · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.